Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer

V. Rusch, D. Klimstra, E. Venkatraman, J. Oliver, N. Martini, R. Gralla, M. Kris, Richard J. Gralla

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

The development of cisplatin-based induction chemotherapy followed by surgical resection or radiation has improved the poor prognosis of stage III non-small cell lung cancer (NSCLC). In vitro studies indicate that p53 can modulate cisplatin-induced cytotoxicity, but the molecular genetic features determining response or resistance to cisplatin in vivo must be defined. For this reason, tumor specimens from 52 patients with stage IIIA NSCLC entered in a prospective clinical trial of cisplatin-based induction chemotherapy followed by surgical resection were examined for p53 expression by immunohistochemical staining before and after induction chemotherapy. p53 expression was correlated with clinical and pathological response using Fisher's exact test. No correlation was established between p53 expression and clinical response because 47 of the 52 patients studied had a major response. However, a significant association was observed between aberrant p53 expression and resistance to chemotherapy as assessed by pathological response. Only 3 of the 20 patients whose tumors exhibited a high level (++ to ++++) of p53 staining experienced a major (+++ to ++++) pathological response to chemotherapy. Only 7 of 52 cases examined before and after chemotherapy treatment exhibited a change in the level of p53 expression after cisplatin-based chemotherapy. These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC.

Original languageEnglish (US)
Pages (from-to)5038-5042
Number of pages5
JournalCancer Research
Volume55
Issue number21
StatePublished - 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Induction Chemotherapy
Staining and Labeling
Molecular Biology
Neoplasms
Clinical Trials
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rusch, V., Klimstra, D., Venkatraman, E., Oliver, J., Martini, N., Gralla, R., ... Gralla, R. J. (1995). Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Research, 55(21), 5038-5042.

Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. / Rusch, V.; Klimstra, D.; Venkatraman, E.; Oliver, J.; Martini, N.; Gralla, R.; Kris, M.; Gralla, Richard J.

In: Cancer Research, Vol. 55, No. 21, 1995, p. 5038-5042.

Research output: Contribution to journalArticle

Rusch, V, Klimstra, D, Venkatraman, E, Oliver, J, Martini, N, Gralla, R, Kris, M & Gralla, RJ 1995, 'Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer', Cancer Research, vol. 55, no. 21, pp. 5038-5042.
Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Research. 1995;55(21):5038-5042.
Rusch, V. ; Klimstra, D. ; Venkatraman, E. ; Oliver, J. ; Martini, N. ; Gralla, R. ; Kris, M. ; Gralla, Richard J. / Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. In: Cancer Research. 1995 ; Vol. 55, No. 21. pp. 5038-5042.
@article{76c5acfe59584dabb336f9f6fe74bcc7,
title = "Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer",
abstract = "The development of cisplatin-based induction chemotherapy followed by surgical resection or radiation has improved the poor prognosis of stage III non-small cell lung cancer (NSCLC). In vitro studies indicate that p53 can modulate cisplatin-induced cytotoxicity, but the molecular genetic features determining response or resistance to cisplatin in vivo must be defined. For this reason, tumor specimens from 52 patients with stage IIIA NSCLC entered in a prospective clinical trial of cisplatin-based induction chemotherapy followed by surgical resection were examined for p53 expression by immunohistochemical staining before and after induction chemotherapy. p53 expression was correlated with clinical and pathological response using Fisher's exact test. No correlation was established between p53 expression and clinical response because 47 of the 52 patients studied had a major response. However, a significant association was observed between aberrant p53 expression and resistance to chemotherapy as assessed by pathological response. Only 3 of the 20 patients whose tumors exhibited a high level (++ to ++++) of p53 staining experienced a major (+++ to ++++) pathological response to chemotherapy. Only 7 of 52 cases examined before and after chemotherapy treatment exhibited a change in the level of p53 expression after cisplatin-based chemotherapy. These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC.",
author = "V. Rusch and D. Klimstra and E. Venkatraman and J. Oliver and N. Martini and R. Gralla and M. Kris and Gralla, {Richard J.}",
year = "1995",
language = "English (US)",
volume = "55",
pages = "5038--5042",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer

AU - Rusch, V.

AU - Klimstra, D.

AU - Venkatraman, E.

AU - Oliver, J.

AU - Martini, N.

AU - Gralla, R.

AU - Kris, M.

AU - Gralla, Richard J.

PY - 1995

Y1 - 1995

N2 - The development of cisplatin-based induction chemotherapy followed by surgical resection or radiation has improved the poor prognosis of stage III non-small cell lung cancer (NSCLC). In vitro studies indicate that p53 can modulate cisplatin-induced cytotoxicity, but the molecular genetic features determining response or resistance to cisplatin in vivo must be defined. For this reason, tumor specimens from 52 patients with stage IIIA NSCLC entered in a prospective clinical trial of cisplatin-based induction chemotherapy followed by surgical resection were examined for p53 expression by immunohistochemical staining before and after induction chemotherapy. p53 expression was correlated with clinical and pathological response using Fisher's exact test. No correlation was established between p53 expression and clinical response because 47 of the 52 patients studied had a major response. However, a significant association was observed between aberrant p53 expression and resistance to chemotherapy as assessed by pathological response. Only 3 of the 20 patients whose tumors exhibited a high level (++ to ++++) of p53 staining experienced a major (+++ to ++++) pathological response to chemotherapy. Only 7 of 52 cases examined before and after chemotherapy treatment exhibited a change in the level of p53 expression after cisplatin-based chemotherapy. These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC.

AB - The development of cisplatin-based induction chemotherapy followed by surgical resection or radiation has improved the poor prognosis of stage III non-small cell lung cancer (NSCLC). In vitro studies indicate that p53 can modulate cisplatin-induced cytotoxicity, but the molecular genetic features determining response or resistance to cisplatin in vivo must be defined. For this reason, tumor specimens from 52 patients with stage IIIA NSCLC entered in a prospective clinical trial of cisplatin-based induction chemotherapy followed by surgical resection were examined for p53 expression by immunohistochemical staining before and after induction chemotherapy. p53 expression was correlated with clinical and pathological response using Fisher's exact test. No correlation was established between p53 expression and clinical response because 47 of the 52 patients studied had a major response. However, a significant association was observed between aberrant p53 expression and resistance to chemotherapy as assessed by pathological response. Only 3 of the 20 patients whose tumors exhibited a high level (++ to ++++) of p53 staining experienced a major (+++ to ++++) pathological response to chemotherapy. Only 7 of 52 cases examined before and after chemotherapy treatment exhibited a change in the level of p53 expression after cisplatin-based chemotherapy. These results indicate that cisplatin alters p53 expression infrequently and suggest a direct link between aberrant p53 expression and resistance to cisplatin-based chemotherapy in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0028840535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028840535&partnerID=8YFLogxK

M3 - Article

C2 - 7585548

AN - SCOPUS:0028840535

VL - 55

SP - 5038

EP - 5042

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -